Peresolimab is a humanized immunoglobulin G1 kappa (IgG1-κ) monoclonal antibody designed to target the programmed cell death protein 1 (PD-1) receptor, and it potentially functions by stimulating physiological immune inhibitory pathways to restore immune homeostasis and maintain self-tolerance, which can be applied in the research of autoimmune conditions such as rheumatoid arthritis.